ArticleFrontiers in pharmacology2026
Qingre-Huatan-Liqi formula attenuates FPM-induced lung injury via modulation of MAPK signaling and NETs formation.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Fine particulate matter (PM2.5, FPM) can induce and exacerbate chronic obstructive pulmonary disease (COPD) by triggering oxidative stress and multiple other pathogenic pathways. Our previous studies have demonstrated that Qingre-Huatan-Liqi formula (QRHTLQ) can improve the symptoms of patients with acute exacerbation of COPD (AECOPD), and animal experiments have suggested that QRHTLQ may prevent AECOPD via the EGFR-PI3K-AKT pathway. However, the protective effects and precise mechanisms by which QRHTLQ attenuates FPM-induced lung injury remain unclear. Methods: FPM-induced lung injury models were established by repeated intratracheal instillations of FPM every 3 days. Thirty rats were randomly divided into control, model, low-dose QRHTLQ, medium-dose QRHTLQ, high-dose QRHTLQ, and erythromycin groups. The therapeutic effects of QRHTLQ were evaluated by H&E staining and qPCR. LC-MS was used to identify blood-absorbed active constituents of QRHTLQ. Proteomics combined with network pharmacology was applied to identify key targets. The effects of QRHTLQ on these targets and related processes were validated by immunofluorescence, ELISA, and Western blot. Molecular docking and molecular dynamics simulations were performed to evaluate constituent-target binding and complex stability. Results: QRHTLQ alleviated FPM-triggered airway inflammation, downregulated pulmonary IL-6, IL-1β, TNF-α mRNA as well as ROS levels in bronchoalveolar lavage fluid (BALF). Six major blood-absorbed active constituents were identified using LC-MS. Integrated analyses suggested that QRHTLQ interferes with neutrophil extracellular traps (NETs) formation, with MAPK14 (P38α, the major isoform of P38 MAPK) identified as a core target. QRHTLQ decreased PAD4 in BALF and lung tissue, reduced NETs levels in lung tissue, and decreased the p-P38/P38 ratio. Baicalin exhibited the most favorable binding energy with MAPK14, and molecular dynamics simulations demonstrated that the baicalin-P38 MAPK14 complex was structurally stable. Conclusion: QRHTLQ alleviates FPM-induced lung injury by modulating MAPK signaling and inhibiting NETs formation. Baicalin is likely a key blood-absorbed active component through which QRHTLQ exerts these protective effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.